Detailed Information

Cited 23 time in webofscience Cited 26 time in scopus
Metadata Downloads

Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer

Authors
Cho, Yu KyungChoi, Myung-GyuChoi, Suck CheiLee, Kee MyungKim, Tae OhPark, Soo-HeonMoon, Jeong SeopLim, Yun JeongKang, Dae HwanCheon, Gab JinBaik, Gwang HoKim, Kyoung OhCho, Kwang BumJang, Jin SeokPark, Jong-JaeSon, Byoung KwanJung, Hye-KyungKim, Byung-WookKim, Sung KukLee, Soo TeikCha, Jae MyungKim, Ah RongKim, Eun JiPark, Hyun WookSong, Geun Seog
Issue Date
Sep-2020
Publisher
Blackwell Publishing Inc.
Citation
Alimentary Pharmacology and Therapeutics, v.52, no.5, pp 789 - 797
Pages
9
Indexed
SCIE
SCOPUS
Journal Title
Alimentary Pharmacology and Therapeutics
Volume
52
Number
5
Start Page
789
End Page
797
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/33609
DOI
10.1111/apt.15865
ISSN
0269-2813
1365-2036
Abstract
Background Tegoprazan is a novel potassium-competitive acid blocker for the treatment of acid-related disorders. Aims To assess whether tegoprazan is non-inferior to lansoprazole in terms of efficacy and safety in patients with gastric ulcers. Methods In this phase 3, double-blind, active control, multicentre study, 306 gastric ulcer patients were randomised to one of three treatment groups: tegoprazan 50 mg, tegoprazan 100 mg and lansoprazole 30 mg once daily for 4 or 8 weeks. The primary endpoint was the cumulative proportion of patients with healed ulcers confirmed by endoscopy up to 8 weeks from treatment initiation. Symptoms and safety were assessed. Results In the full analysis set, the cumulative healing rates at week 8 were 94.8% (91/96) for the tegoprazan 50 mg, 95.0% (94/99) for the tegoprazan 100 mg and 95.7% (89/93) for the lansoprazole 30 mg groups. At week 4, the respective healing rates were 90.6% (87/96), 91.9% (91/99), and 89.2% (83/93). In per protocol analysis, 4-week healing rates were 95.4% (84/88), 94.6% (88/93) and 92.9% (79/85) for tegoprazan 50 mg, tegoprazan 100 mg and lansoprazole 30 mg, respectively. Both doses of tegoprazan were non-inferior to lansoprazole in ulcer healing at 4 and 8 weeks. The incidence of drug-related treatment-emergent adverse events did not differ among groups. The increase in serum gastrin concentration was not higher in tegoprazan-treated patients than in lansoprazole-treated patients. Conclusions Tegoprazan 50 or 100 mg were not inferior to lansoprazole 30 mg once daily in the treatment of gastric ulcers.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Park, Jong Jae photo

Park, Jong Jae
Guro Hospital (Department of Gastroenterology and Hepatology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE